@article{APS9383,
author = {Jing-yun Li and Yu-peng Ren and Yin Yuan and Shuang-min Ji and Shu-pei Zhou and Li-jie Wang and Zhen-zhen Mou and Liang Li and Wei Lu and Tian-yan Zhou},
title = {Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice},
journal = {Acta Pharmacologica Sinica},
volume = {37},
number = {7},
year = {2017},
keywords = {},
abstract = {Aim: Combined therapy of EGFR TKI and VEGFR TKI may produce a greater therapeutic benefit and overcome EGFR TKI-induced resistance. However, a previous study shows that a combination of EGFR TKI erlotinib (ER) with VEGFR TKI sunitinib (SU) did not improve the overall survival in patients with non-small-cell lung cancer (NSCLC). In this study we examined the anticancer effect of ER, SU and their combination in the treatment of A549 human NSCLC xenograft mice, and conducted PK/PD modeling and simulations to optimize the dose regimen.
Methods: ER (20, 50 mg·kg−1·d−) or SU (5, 10, 20 mg·kg−·d−) alone, or their combination were administered to BALB/c nude mice bearing A549 tumors for 22 days. The tumor size and body weight were recorded daily. The experimental data were used to develop PK/PD models describing the quantitative relationship between the plasma concentrations and tumor suppression in different dose regimens. The models were further evaluated and validated, and used to predict the efficacy of different combination regimens and to select the optimal regimen.
Results: The in vivo anticancer efficacy of the combination groups was much stronger than that of either drug administered alone. A PK/PD model was developed with a combination index (φ) of 4.4, revealing a strong synergistic effect between ER and SU. The model simulation predicted the tumor growth in different dosage regimens, and showed that the dose of SU played a decisive role in the combination treatment, and suggested that a lower dose of ER (≤5 mg·kg−·d−) and adjusting the dose of SU might yield a better dosage regimen for clinical research.
Conclusion: The experimental data and modeling confirm synergistic anticancer effect of ER and SU in the treatment of A549 xenograft mice. The optimal dosage regimen determined by the PK/PD modeling and simulation can be used in future preclinical study and provide a reference for clinical application.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/9383}
}